An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy as First-Line Treatment in Patients With Advanced Ovarian Cancer (OSCAR 1)
This multicenter, prospective, observational study will evaluate the safety and efficacy of Avastin (bevacizumab) in combination with chemotherapy as first-line treatment in patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in routine clinical practice. Eligible patients will be followed for approximately 15 months.
Ovarian Cancer
Progression-free survival, defined as time from first administration of first-line therapy to documented disease progression, approximately 6 years|Safety: Incidence of adverse events, approximately 6 years
Overall survival, defined as time from first administration of first-line therapy to documented death, approximately 6 years|Objective response rate, defined as percentage of patients with complete or partial response according to local assessments, approximately 6 years|Quality of life: EQ-5D/EORTC questionnaires, approximately 6 years|Dosage/schedule/duration of Avastin therapy, approximately 6 years|Composition of first-line chemotherapy regimens: drugs/dosage/duration, approximately 6 years
This multicenter, prospective, observational study will evaluate the safety and efficacy of Avastin (bevacizumab) in combination with chemotherapy as first-line treatment in patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in routine clinical practice. Eligible patients will be followed for approximately 15 months.